Takeda Receives FDA Approval to Expand the Use of Hyqvia to Treat Primary Immunodeficiency in Children
CAMBRIDGE, Mass.--(BUSINESS WIRE) April 11, 2023 --Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental biologics license application (sBLA) to expand the use of Hyqvia to treat... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 11, 2023 Category: Drugs & Pharmacology Source Type: news

FDA Greenlights First Drug for Rare Immunodeficiency Disease
(MedPage Today) -- The FDA approved leniolisib (Joenja) on Friday as the first treatment indicated for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare genetic disorder that causes progressive primary immunodeficiency. Leniolisib... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 27, 2023 Category: American Health Source Type: news

Association of primary immunodeficiencies in parents with psychiatric disorders and suicidal behavior in their offspring - Isung J, Isomura K, Williams K, Zhang T, Lichtenstein P, Fern ández de la Cruz L, Sidorchuk A, Mataix-Cols D.
IMPORTANCE: Maternal immune activation (MIA) leading to altered neurodevelopment in utero is a hypothesized risk factor for psychiatric outcomes in offspring. Primary antibody immunodeficiencies (PIDs) constitute a unique natural experiment to test the MIA... (Source: SafetyLit)
Source: SafetyLit - February 6, 2023 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Detection of a Highly Divergent Type 3 Vaccine-Derived Poliovirus in a Child with a Severe Primary Immunodeficiency Disorder - Chongqing, China, 2022
This report describes a case of vaccine-derived poliovirus in a child with an immunodeficiency disorder in China. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - September 8, 2022 Category: American Health Tags: MMWR Morbidity & Mortality Weekly Report Polio (poliomyelitis) Polio Vaccination Source Type: news

COV-AD study sheds further light on reduced COVID-19 vaccine effectiveness for people with immunodeficiency, UK Covid Vaccine Research Hub
New findings from the COV-AD study team have shown that people with immunodeficiency are considerably less likely to generate antibodies to fight COVID-19 following vaccination. Immunodeficiency can arise from a wide range of conditions, and sometimes from the treatments people receive for an illness. Primary immunodeficiency occurs as a result of genetic factors, while secondary immunodeficiency is usually caused by an illness such as blood cancer. People with immunodeficiency are at risk of severe and recurrent infection, and often don ' t respond well to vaccination. The study team recruited 320 people with immunodefi...
Source: Current Awareness Service for Health (CASH) - June 9, 2022 Category: Consumer Health News Source Type: news

Strong evidence to support use of third primary vaccine dose in people with weakened immune systems, UK Covid Vaccine Research Hub
New research from the team behind the COV-AD study has uncovered ' strong data ' to support the policy of giving a third primary dose of vaccine to people with weakened immune systems. The study, published as a preprint, looked at immune responses in 161 people with immune deficiency, with blood samples being taken at various timepoints before and after their third dose of vaccine. People with both primary and secondary immunity were included in the study – primary immunodeficiency occurs as a result of genetic factors, while secondary immunodeficiency is usually caused by illness. The results were compared with those o...
Source: Current Awareness Service for Health (CASH) - April 7, 2022 Category: Consumer Health News Source Type: news

Primary Immunodeficiencies Linked to Early-Onset GI Cancers Primary Immunodeficiencies Linked to Early-Onset GI Cancers
This study was published on medRxiv.org as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 7, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

When mad AIOLOS drags IKAROS down: A novel pathogenic mechanism
(Tokyo Medical and Dental University) Researchers from TMDU have described a novel primary immunodeficiency due to a mutation in AIOLOS. This acts through a novel pathogenic mechanism termed " heterodimeric interference " , whereby when two different proteins bind together in a heterodimer, the mutant protein hijacks the function of the normal protein. In a mouse model, they were able to restore some of the lost functions by interfering with the mutated protein, suggesting a possible therapeutic approach to disorders of this nature. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 16, 2021 Category: International Medicine & Public Health Source Type: news

Link Between Primary Immunodeficiencies and Rheumatic Diseases Link Between Primary Immunodeficiencies and Rheumatic Diseases
"A rheumatologist may be treating the rheumatic manifestations of a primary immunodeficiency disorder," the study ' s lead author, Georgios Sogkas, MD, PhD, said in an interview.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 22, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news

COVID-19 Outcomes Vary Widely in Patients With Primary Immunodeficiencies COVID-19 Outcomes Vary Widely in Patients With Primary Immunodeficiencies
Clinical outcomes of COVID-19 in patients with primary immunodeficiency diseases range from mild illness to death, according to a small case series.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - October 20, 2020 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

Epidemiology, Clinical and Microbiologic Profile and Risk Factors for Inpatient Mortality in Pediatric Severe Sepsis in the United States From 2003 to 2014: A Large Population Analysis
OBJECTIVE: To evaluate the national trends in pediatric severe sepsis in the United States from 2003 to 2014. STUDY DESIGN: For this study, we included nonoverlapping years of Kids Inpatient database and National Inpatient Sample database while including hospitalizations of children between 1 and 20 years of age from more than 4200 hospitals across the United States. We identified patient hospitalizations with severe sepsis using specific ICD codes and modified Angus Criteria. Trend analysis of various factors associated with severe sepsis was calculated using the Cochrane-Armitage test. Associated foci of infection and co...
Source: Current Awareness Service for Health (CASH) - September 3, 2020 Category: Consumer Health News Source Type: news

CSL Behring and Seattle Children's Research Institute to advance gene therapy treatments
(Seattle Children's) Seattle Children's Research Institute, one of the top pediatric research institutions in the world, and global biotechnology leader CSL Behring announced a strategic alliance to develop stem cell gene therapies for primary immunodeficiency diseases. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 2, 2020 Category: International Medicine & Public Health Source Type: news

What Causes Neutropenia?
Discussion Neuropenia is defined as a neutrophil count < 1500/µL. It is classified as mild from 1000-1500/µL, moderate from 500-1000/µL, and severe if < 500/µL. It is not uncommonly seen in the setting of acute self-limited infections, and with re-testing returns to normal. It is also not uncommon at certain ages, such as perinatally, especially in premature infants (up to 6%) . It is also common in certain ethnic groups particularly African American or Arabic populations where up to 10% of the children may have mild neutropenia which does not cause clinical disease. The overall prevalence a...
Source: PediatricEducation.org - March 2, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Invasive Pneumococcal Disease in Kids Suggests Underlying Immunodeficiency Invasive Pneumococcal Disease in Kids Suggests Underlying Immunodeficiency
Invasive pneumococcal disease (IPD) in children without known risk factors could be a marker of underlying primary immunodeficiency (PID), according to a systematic review.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 3, 2019 Category: Allergy & Immunology Tags: Pediatrics News Source Type: news

FDA OKs Immunoglobulin Xembify for Primary Immunodeficiencies FDA OKs Immunoglobulin Xembify for Primary Immunodeficiencies
Xembify is a 20% immune globulin solution for subcutaneous injection indicated to treat primary immunodeficiencies in patients aged 2 years and older.FDA Approvals (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - July 6, 2019 Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Alert Source Type: news